2018
DOI: 10.1080/14656566.2018.1537368
|View full text |Cite
|
Sign up to set email alerts
|

Current and emerging pharmacotherapy for ischemic stroke prevention in patients with atrial fibrillation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2020
2020
2021
2021

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 73 publications
0
2
0
Order By: Relevance
“…For this reason, the research of new safer and efficient compounds lead to the discovery of a novel VKA, tecarfarin (ATI-5923, Figure 50 ), currently under development [ 195 ]. Tecarfarin is active after oral administration and acts as a vitamin-K epoxide reductase (VKOR) inhibitor; unlike warfarin, is not metabolized by the cytochrome P450 system but by human carboxylesterase-2 ( h CE-2) in hepatic microsomes.…”
Section: Biological Activitiesmentioning
confidence: 99%
“…For this reason, the research of new safer and efficient compounds lead to the discovery of a novel VKA, tecarfarin (ATI-5923, Figure 50 ), currently under development [ 195 ]. Tecarfarin is active after oral administration and acts as a vitamin-K epoxide reductase (VKOR) inhibitor; unlike warfarin, is not metabolized by the cytochrome P450 system but by human carboxylesterase-2 ( h CE-2) in hepatic microsomes.…”
Section: Biological Activitiesmentioning
confidence: 99%
“…In spite of efficiency in addition with the benefits of an oral treatment, warfarin is not lacking of side-effects used as effective anti-coagulant agent. [37][38].…”
Section: Anticoagulant Activitymentioning
confidence: 99%